Brigacent 180 mg (Tablet)
Unit Price: ৳ 2,000.00 (1 x 7: ৳ 14,000.00)
Strip Price: ৳ 14,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Brigatinib |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of ALK-positive metastatic Non-small cell lung cancer (NSCLC)
- Patients who have progressed on or are intolerant to Crizotinib
Pharmacology
- Inhibition of ALK, ROS1, IGF-1R, and FLT-3
- Inhibition of autophosphorylation of ALK and downstream signaling proteins
- Inhibition of EML4-ALK-positive NSCLC xenograft growth in mice
- Absorption time range: 1 to 4 hours
- Plasma protein binding: 66%
- Blood to plasma concentration ratio: 0.69
- Distribution volume at steady state: 153 L
- Mean apparent oral clearance at steady state: 12.7 L/h
- Plasma elimination half-life: 25 hours
- Metabolism by CYP2C8 and CYP3A4
- Excretion: 65% in feces, 25% in urine
Dosage & Administration
- 90 mg orally once daily for the first 7 days
- If tolerated, increase to 180 mg orally once daily
- Administer until disease progression or unacceptable toxicity
- Resumption after interruption for 14 days
- Tablets should be swallowed whole
- Pediatric use not established
Interaction
- Drugs increasing plasma concentrations
- Drugs decreasing plasma concentrations
- Drugs altering plasma concentrations
Contraindications
- Known hypersensitivity to Brigatinib or any other components
Side Effects
- Interstitial Lung Disease (ILD)/Pneumonitis
- Hypertension
- Bradycardia
- Visual Disturbance
- Creatine Phosphokinase (CPK) Elevation
- Pancreatic Enzyme Elevation
- Hyperglycemia
Pregnancy & Lactation
- Lack of clinical data in pregnant women
- Advisory against breastfeeding
- Need for effective contraception
- Potential for reduced male fertility
Precautions & Warnings
- Interstitial Lung Disease (ILD)/Pneumonitis evaluation
- Hypertension control and monitoring
- Bradycardia monitoring
- Visual Disturbance reporting and evaluation
- Creatine Phosphokinase (CPK) monitoring
- Pancreatic Enzyme monitoring
- Hyperglycemia assessment and management
Therapeutic Class
- Cytotoxic Chemotherapy
Storage Conditions
- Keep below 30°C
- Away from light & moisture
- Keep out of the reach of children